Compare Mercadolibre Inc (MELI) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs 22nd Century Group Inc — how do they compare? Mercadolibre Inc trades at $1,895 (market cap $94.13B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: Mercadolibre Inc is far larger — about 151414.7× 22nd Century Group Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mercadolibre Inc for 117 Days and 22nd Century Group Inc for 32 Days on average.
| MELI | XXII | |
|---|---|---|
Market Cap | $94.13B | $621.67K |
Volume | 273,781 | 45,625 |
Sector | Consumer Cyclical | Consumer Staples |
52-Week High | $2.36K | $483.00 |
52-Week Low | $1.55K | $0.80 |
Typical Hold Time | 117 Days | 32 Days |
Enterprise Value | $101.77B | -$3.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,889.85, up 0.91% on the day, with a bullish technical signal and strong analyst support. Revenue grew to $28.89 billion in 2025, though net income margin dipped to 6.91%. The company is expanding its fintech ecosystem, with credit portfolio surging 75% to $16.4 billion in Q2 2026. Operating cash flow remains robust at $12.12 billion, supporting aggressive investment in logistics and market expansion across Latin America.
Outlook is positive given dominant market position and integrated e-commerce-fintech model, but valuation multiples like P/E of 50.51 suggest high growth expectations. Risks include macroeconomic pressures in key markets like Argentina and intense regional competition. Analyst consensus is strongly bullish with a $2,170 price target, indicating ~15% upside from current levels.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
